protein

Recombinant Human Inositol Monophosphatase 1

MBS144249

0.005 mg

140 USD

Recombinant Protein

Recombinant Human Inositol Monophosphatase 1

Inositol Monophosphatase 1

IMPA1 Human; Inositol Monophosphatase 1 Human Recombinant; Inositol monophosphatase 1; IMP 1; IMPase 1; Inositol-1(or 4)-monophosphatase 1; Lithium-sensitive myo-inositol monophosphatase A1; IMPA1; IMPA; IMP

inositol monophosphatase 1 isoform 2; Inositol monophosphatase 1; inositol monophosphatase 1; D-galactose 1-phosphate phosphatase; IMP 1; IMPase 1; inositol-1(or 4)-monophosphatase 1; lithium-sensitive myo-inositol monophosphatase A1; inositol(myo)-1(or 4)-monophosphatase 1; D-galactose 1-phosphate phosphatase

IMPA1

IMPA1; IMPA1; IMP; IMPA; IMP 1; IMPase 1

IMPA1_HUMAN

E Coli

336

MGSSHHHHHH SSGLVPRGSH MADPWQECMD YAVTLARQAG EVVCEAIKNE MNVMLKSSPV DLVTATDQKV EKMLISSIKE KYPSHSFIGE ESVAAGEKSI LTDNPTWIID PIDGTTNFVH RFPFVAVSIG FAVNKKIEFG VVYSCVEGKM YTARKGKGAF CNGQKLQVSQ QEDITKSLLV TELGSSRTPE TVRMVLSNME KLFCIPVHGI RSVGTAAVNM CLVATGGADA YYEMGIHCWD VAGAGIIVTE AGGVLMDVTG GPFDLMSRRV IAANNRILAE RIAKEIQVIP LQRDDED.

Greater than 95.0% as determined by SDS-PAGE.

The IMPA1 solution (1 mg/ml) contains 20mM Tris-HCl Buffer (pH 8.0) and 10% Glycerol. Sterile Filtered colorless solution.

Store at 4 degree C if entire vial will be used within 2-4 weeks. Store, frozen at -20 degree C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.

ENZYMES; Enzymes; Phosphatase

Description: IMPA1 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E Coli is a single, non-glycosylated, polypeptide chain containing 297 amino acids (1-277 a.a.) and having a molecular mass of 32.3kDa. The IMPA1 is purified by proprietary chromatographic techniques. Introduction: Inositol monophosphatase1 (IMPA1) is responsible for the provision of inositol essential for synthesis of phosphatidylinositol and polyphosphoinositides. IMPA1 has a central role in the phosphatidylinositol signaling pathway by catalyzing the hydrolysis of inositol monophosphates. IMPA1 has been recognized as the pharmacological target for lithium action in the brain. The IMPA1 enzyme has a magnesium-dependent phosphatase activity and is inhibited by therapeutic concentrations of lithium. Inhibition of inositol monophosphate hydroylosis and ensuing depletion of inositol for phosphatidylinositol synthesis may perhaps explain the anti-manic and anti-depressive effects of lithium administered to treat bipolar disorder.

221625487

NP_001138350.1

NM_001144878.1

P29218

36,695 Da

D-myo-inositol (1,4,5)-trisphosphate Degradation Pathway (545327); D-myo-inositol (1,4,5)-trisphosphate Degradation Pathway (138942); Inositol Phosphate Metabolism Pathway (82987); Inositol Phosphate Metabolism Pathway (730320); Inositol Phosphate Metabolism Pathway (362); Inositol Phosphate Metabolism, Ins(1,3,4,5)P4 = Ins(1,3,4)P3 = Myo-inositol Pathway (413401); Inositol Phosphate Metabolism, Ins(1,3,4,5)P4 = Ins(1,3,4)P3 = Myo-inositol Pathway (468324); Integrated Breast Cancer Pathway (219801); Metabolic Pathways (132956); Metabolism Pathway (477135)

This gene encodes an enzyme that dephosphorylates myo-inositol monophosphate to generate free myo-inositol, a precursor of phosphatidylinositol, and is therefore an important modulator of intracellular signal transduction via the production of the second messengers myoinositol 1,4,5-trisphosphate and diacylglycerol. This enzyme can also use myo-inositol-1,3-diphosphate, myo-inositol-1,4-diphosphate, scyllo-inositol-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates. This enzyme shows magnesium-dependent phosphatase activity and is inhibited by therapeutic concentrations of lithium. Inhibition of inositol monophosphate hydroylosis and subsequent depletion of inositol for phosphatidylinositol synthesis may explain the anti-manic and anti-depressive effects of lithium administered to treat bipolar disorder. Alternative splicing results in multiple transcript variants encoding distinct isoforms. A pseudogene of this gene is also present on chromosome 8q21.13. [provided by RefSeq, Dec 2014]

IMPA1: Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol- phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1- phosphate, beta-glycerophosphate, and 2 -AMP as substrates. Belongs to the inositol monophosphatase family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: EC 3.1.3.94; Phosphatase (non-protein); Motility/polarity/chemotaxis; Carbohydrate Metabolism - inositol phosphate; EC 3.1.3.25. Chromosomal Location of Human Ortholog: 8q21.13-q21.3. Cellular Component: cytoplasm; cytosol. Molecular Function: identical protein binding; protein homodimerization activity; manganese ion binding; inositol-1(or 4)-monophosphatase activity; magnesium ion binding; lithium ion binding. Biological Process: inositol phosphate metabolic process; phosphoinositide phosphorylation; inositol biosynthetic process; inositol phosphate dephosphorylation; phosphatidylinositol biosynthetic process; signal transduction; phosphate metabolic process

0.005 mg

140 USD

0.02 mg

205

1 mg

2665